Atossa Therapeutics, Inc. (ATOS)
Develops oral medications to treat and prevent breast cancer.
$2.42+0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-80.4%
The outlook
ATOS is trading near its 52-week lows and below both short and long-term moving averages, reflecting weak recent momentum. Analyst coverage shows a stark disconnect: the average price target sits roughly 8x the current price, though the overall sentiment leans bearish. The stock remains deeply depressed in its yearly range, with technical indicators offering little support.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +811% vs current price
Analyst price target
~12-month · 3 analysts$22.00average target+811.0% vs now
Now $2.42
Low $20.00High $24.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$24.1M
52-wk high
$19.35
52-wk low
$1.70
50-day avg
$3.23
200-day avg
$7.24
Trailing P/E
—